Steve Schonfeld’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-16,872
| Closed | -$403K | – | 2595 |
|
|
2025
Q3 | $403K | Sell |
16,872
-39,451
| -70% | -$742K | ﹤0.01% | 1745 |
|
|
2025
Q2 | $834K | Sell |
56,323
-69,475
| -55% | -$1.15M | 0.01% | 1364 |
|
|
2025
Q1 | $2.25M | Buy |
125,798
+102,798
| +447% | +$2.09M | 0.01% | 906 |
|
|
2024
Q4 | $401K | Sell |
23,000
-152,820
| -87% | -$2.7M | ﹤0.01% | 1496 |
|
|
2024
Q3 | $2.46M | Sell |
175,820
-9,303
| -5% | -$96.9K | 0.02% | 801 |
|
|
2024
Q2 | $1.52M | Sell |
185,123
-255,834
| -58% | -$1.72M | 0.01% | 1025 |
|
|
2024
Q1 | $3.4M | Sell |
440,957
-288,052
| -40% | -$2.43M | 0.02% | 784 |
|
|
2023
Q4 | $6.55M | Buy |
729,009
+205,009
| +39% | +$1.49M | 0.04% | 452 |
|
|
2023
Q3 | $4.68M | Buy |
524,000
+218,371
| +71% | +$3.08M | 0.04% | 566 |
|
|
2023
Q2 | $4.69M | Buy |
305,629
+17,871
| +6% | +$325K | 0.04% | 505 |
|
|
2023
Q1 | $6.47M | Buy |
+287,758
| New | +$6.12M | 0.06% | 379 |
|
|
2022
Q4 | – | Sell |
-27,964
| Closed | -$689K | – | 3021 |
|
|
2022
Q3 | $689K | Sell |
27,964
-13,145
| -32% | -$340K | 0.01% | 1525 |
|
|
2022
Q2 | $996K | Buy |
41,109
+30,109
| +274% | +$757K | 0.01% | 1029 |
|
|
2022
Q1 | $284K | Sell |
11,000
-2,100
| -16% | -$55.8K | ﹤0.01% | 1726 |
|
|
2021
Q4 | $407K | Buy |
13,100
+3,400
| +35% | +$95.8K | ﹤0.01% | 1372 |
|
|
2021
Q3 | $235K | Sell |
9,700
-12,260
| -56% | -$225K | ﹤0.01% | 1683 |
|
|
2021
Q2 | $320K | Buy |
+21,960
| New | +$433K | ﹤0.01% | 1432 |
|
|
2021
Q1 | – | Sell |
-122,819
| Closed | -$3.35M | – | 2134 |
|
|
2020
Q4 | $3.35M | Buy |
+122,819
| New | +$2.87M | 0.05% | 494 |
|
|
2020
Q1 | – | Sell |
-141,489
| Closed | -$2.01M | – | 1536 |
|
|
2019
Q4 | $2.01M | Buy |
+141,489
| New | +$1.81M | 0.05% | 337 |
|
|
2019
Q2 | – | Sell |
-30,500
| Closed | -$691K | – | 1255 |
|
|
2019
Q1 | $691K | Sell |
30,500
-50,800
| -62% | -$1.12M | 0.02% | 609 |
|
|
2018
Q4 | $1.84M | Sell |
81,300
-19,700
| -20% | -$490K | 0.07% | 347 |
|
|
2018
Q3 | $2.9M | Buy |
+101,000
| New | +$2.89M | 0.13% | 215 |
|
|
2017
Q1 | – | Sell |
-30,418
| Closed | -$576K | – | 743 |
|
|
2016
Q4 | $576K | Sell |
30,418
-10,175
| -25% | -$208K | 0.07% | 314 |
|
|
2016
Q3 | $909K | Buy |
+40,593
| New | +$773K | 0.15% | 187 |
|
Other funds holding TVTX
PA
NAMI
AC
Steve Schonfeld's TVTX Position: Q4 2025 in Review
Steve Schonfeld sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 16,872 shares — an estimated $403K sold.
Steve Schonfeld first reported a position in TVTX in Q3 2016 and held it in 24 quarters. The position peaked at $6.55M in Q4 2023. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.
- Steve Schonfeld reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
- Steve Schonfeld sold 16,872 Travere Therapeutics shares in Q4 2025, an estimated $403K.
- Steve Schonfeld first reported a position in Travere Therapeutics in Q3 2016 and held it in 24 quarters.
- Steve Schonfeld's Travere Therapeutics position peaked at $6.55M in Q4 2023.
- 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.